Spinogenix
CompanyUnited States
Spinogenix develops one asset, in phase 2 (Tazbentetol in ALS). Mostly small molecule; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 2
- 5
- Trials
- 0
- Signals
Pipeline
1Oral transient activator of glutamatergic synapses promoting synaptic regeneration
Phase 2, Small molecule, ALS, Alzheimer's disease
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Trials5
- Signals2
- Similar companies6